Esuberaprost

Summary

Esuberaprost (CHEMBL3137314) is a phase-3 clinical-stage small molecule targeting PTGIR; indicated across 1 condition including pulmonary arterial hypertension.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (PTGIR)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 398.5 Da · C24H30O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3137314
Name	Esuberaprost
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10501053
Molecular formula	C24H30O5
Molecular weight	398.5
InChIKey	CTPOHARTNNSRSR-NOQAJONNSA-N

SMILES: CC#CC[C@H](C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)O)O)O

IUPAC name: 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S,4S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid

Also known as: Aps-314d free acid, Aps-314d, BPS-314d, Esuberaprost, ESUBERAPROST

Parent form; salt/anhydrous children: CHEMBL3137337, CHEMBL4298145

Patent coverage: 39 distinct patent families (120 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 75 (62%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGIR	IP receptor	Agonist	7.89	0.2%	P43119

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): PTGIR.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGIR
Prostacyclin signalling through prostacyclin receptor	1	PTGIR
G alpha (s) signalling events	1	PTGIR

Dominant GO biological processes

GO term	Targets
inflammatory response	1
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
positive regulation of cytosolic calcium ion concentration	1
cell-cell signaling	1
negative regulation of platelet-derived growth factor receptor signaling pathway	1
response to lipopolysaccharide	1
negative regulation of smooth muscle cell proliferation	1
signal transduction	1
G protein-coupled receptor signaling pathway	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pulmonary arterial hypertension	3	MONDO:0015924	EFO:0001361

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03657095	PHASE3	TERMINATED	A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

16 molecules share ≥1 primary target. Top 16 by shared-target count:

Molecule	Source	Status	Shared targets
ALPROSTADIL	ChEMBL + PubChem	Phase 4 (approved)	PTGIR
DINOPROSTONE	ChEMBL + PubChem	Phase 4 (approved)	PTGIR
ILOPROST	ChEMBL + PubChem	Phase 4 (approved)	PTGIR
TREPROSTINIL	ChEMBL + PubChem	Phase 4 (approved)	PTGIR
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGIR
SELEXIPAG	ChEMBL	Phase 4 (approved)	PTGIR
RALINEPAG	ChEMBL	Phase 3	PTGIR
TIMAPIPRANT	ChEMBL	Phase 3	PTGIR
BUTAPROST	ChEMBL	Phase 2	PTGIR
LASELIPAG	ChEMBL	Phase 2	PTGIR
Belzutifan	PubChem	Approved	PTGIR
Dinoprost	PubChem	Approved	PTGIR
epoprostenol	PubChem	Approved	PTGIR
Grapiprant	PubChem	Approved	PTGIR
Indomethacin	PubChem	Approved	PTGIR
Yohimbine	PubChem	Approved	PTGIR